Artigo de periodico

Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study (2022)

• Authors:
  • Aikawa, Nadia E
  • Kupa, Leonard de Vinci Kanda
  • Pasoto, Sandra Gofinet
  • Shinjo, Samuel Katsuyuki
  • Pereira, Rosa Maria Rodrigues
  • Sartori, Ana Marli Christovam
  • Duarte, Alberto José da Silva
  • Antonangelo, Leila
  • Sabino, Ester Cerdeira
  • Menezes, Paulo Rossi
  • Kallas, Esper Georges
  • Silva, Clovis Artur Almeida da
  • Bonfa, Eloisa Silva Dutra de Oliveira
• USP affiliated authors: KUPA, LEONARD DE VINCI KANDA - FM ; SHINJO, SAMUEL KATSUYUKI - FM ; PEREIRA, ROSA MARIA RODRIGUES - FM ; SARTORI, ANA MARLI CHRISTOVAM - FM ; DUARTE, ALBERTO JOSE DA SILVA - FM ; ANTONANGELO, LEILA - FM ; SABINO, ESTER CERDEIRA - FM ; MENEZES, PAULO ROSSI - FM ; KALLAS, ESPER GEORGES - FM ; SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
• Unidade: FM
• DOI: 10.1016/S2665-9913(21)00327-1
• Subjects: IMUNOGENÉTICA; COVID-19; SISTEMA IMUNE; IMUNOGENICIDADE DA VACINA
• Agências de fomento:
  • Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
  • Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)
  • B3-Bolsa de Valores do Brasil
• Language: Inglês
• Imprenta:
  • Publisher place: Amsterdam
  • Date published: 2022
• Source:
  • Título do periódico: Lancet rheumatology
  • ISSN: 2665-9913
  • Volume/Número/Paginação/Ano: v. 4, n. 2, p. E113-E124, 2022

Informações sobre o DOI: 10.1016/S2665-9913(21)00327-1 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: bronze

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  AIKAWA, Nadia E et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, v. 4, n. 2, p. E113-E124, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2665-9913(21)00327-1. Acesso em: 27 abr. 2024.

• APA

  Aikawa, N. E., Kupa, L. de V. K., Pasoto, S. G., Shinjo, S. K., Pereira, R. M. R., Sartori, A. M. C., et al. (2022). Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, 4( 2), E113-E124. doi:10.1016/S2665-9913(21)00327-1

• NLM

  Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1

• Vancouver

  Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
• Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
• Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
• Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
• SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
• Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
• Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus
• Subclinical Reduced Ovarian Reserve in Adult Polymiositis Patients
• Reduced ovarian reserve in patients with adult polymyositis
• Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases